Category Access to Medicine

The People’s Vaccine: Intellectual Property, Access to Essential Medicines, and the Coronavirus COVID-19

[Mattthew Rimmer] Abstract: This paper explores intellectual property and access to essential medicines in the context of the coronavirus COVID-19 public health crisis. It considers policy solutions to counteract vaccine nationalism and profiteering by pharmaceutical companies and vaccine developers. This paper considers the campaign for the development of a People's Vaccine led by the People’s Vaccine Alliance, UNAIDS, Oxfam and Public Citizen.

Applause as Australia Backs Covid Vaccine Patent Waiver

[Julia Conley] Vaccine equity advocates on Wednesday cheered as the Australian government bowed to a months-long pressure campaign demanding a suspension of intellectual property rights for Covid-19 vaccines, after the country's top trade official said he officially supports the push for a "people's vaccine." Trade Minister Dan Tehan told a group of advocates in a private meeting on Tuesday that the Australian government would support a trade-related aspects of intellectual property (TRIPS) waiver proposal, and later confirmed the news to the press.

The Overlooked Role of Copyright in Securing Vaccine Distribution Equity

As the COVID-19 pandemic continues to ravage the globe, we need to consider every avenue that could improve access to critical medicines needed to fight this deadly disease. The primary focus on securing patent waivers under TRIPS makes perfect sense because patents have been the traditional basis for protecting pharmaco-medical innovations, including the technologies for production and delivery. Compulsory access to both patents and trade secrets is critical. But we overlook a crucial weapon in the fight for vaccine distribution equity when we give short shrift to the equally important role that copyright can play in bringing the full weight of technology to bear on this deadly scourge.

Repairing Medical Equipment in Times of Pandemic

[Ofer Tur-Sinai and Leah Chan Grinvald] Abstract: The COVID-19 pandemic that has gripped the world since early 2020 has underscored the need for an effective right to repair medical equipment. As healthcare systems have been pushed to the limit, keeping critical medical equipment (such as ventilators) in working order has become a matter of life and death. Unfortunately, the ability of hospitals and other health care providers to service and fix their medical equipment is often hindered by the tight control that original equipment manufacturers keep over repair of their products. On top of direct contractual restrictions on repair, one of the major difficulties encountered by hospital-based and third-party service providers is the lack of access to service manuals, service keys, schematics, replacement parts, and repair tools. The ability to block access to these critical items is abetted, in large part, by intellectual property laws.

EU Proposals regarding Article 31bis of the TRIPS Agreement in the Context of the COVID-19 Pandemic

[Nirmalya Syam] This Policy Brief presents an analysis of the proposal by the European Union (EU) with regards to Article 31bis of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), as part of a Declaration on the TRIPS Agreement and Public Health in the circumstances of a pandemic. It discusses the EU’s proposed clarifications, why Article31bis does not provide an effective solution to promote access to pharmaceutical products and possible options.

Promotion of TRIPS-Plus Intellectual Property Provisions Through the Special 301 Review: How Did It Change During the COVID-19 Pandemic?

[Mike Palmedo] This post introduces my chapter the Special 301 Report in the newly-published book Intellectual Property and Access to Medicines.  The chapter, titled “Unilateral Norm Setting Using Special 301” focuses on Special 301 listings from 2009 to 2020 related to intellectual property policies that can be used to access generic medicines. This post will also describe the Special 301 listings in the 2021 Special 301 Report, which was released after the Covid-19 pandemic had taken hold. There were some differences in the 2021 Report pertaining to specific TRIPS flexibilities useful in the fight against Covid-19. However, much of the 2021 Report was similar to the reports released before the pandemic – the Report still criticized countries for policies that could help the fight against Covid-19.

Addressing Exclusivity Issues During the COVID-19 Pandemic and Beyond

[Michael S. Sinha, Sven Bostyn, and Timo Minssen] Abstract: ... This chapter addresses exclusivity issues, with a particular emphasis on regulatory exclusivities for vaccines and therapeutics. We begin with a basic overview of the current regulatory exclusivity landscape in Europe and the US, followed by a discussion of current developments in COVID-19 vaccines and therapeutics. Next, we describe the influence of these technological developments on debates surrounding regulatory exclusivities while describing their relationship to other forms of exclusivities. From these assessments, we draw some lessons for market exclusivity, innovation, and access during the COVID-19 pandemic and beyond.

The Proposed TRIPS Waiver and Pharmaceutical Industry’s Concerns about Counterfeit COVID-19 Vaccines

[Muhammad Zaheer Abbas] Submission to the Australian Parliament’s Joint Committee on Law Enforcement Inquiry into Vaccine Related Fraud and Security Risks - Executive Summary: Australia needs to support the proposal of temporarily waiving intellectual property protections to scale up production and supply of vaccines and other COVID-19 related treatments and diagnostics. The Brand-name pharmaceutical industry’s claim that the proposed TRIPS waiver will result in the proliferation of counterfeit vaccines and treatments is not supported by empirical evidence.

The TRIPS COVID-19 Waiver, Challenges for Africa and Decolonizing Intellectual Property

[Yousuf Vawda] The intellectual property (IP) regimes of African countries are a function of their colonial past, which imposed strong protections, and which have been entrenched through the Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS Agreement). This has had a devastating effect on their ability to access necessary health products both before and during the current COVID-19 pandemic. It is important to reflect on the challenges that African countries face, before considering the implications of the WTO TRIPS waiver on COVID-19 (henceforth, waiver). In assessing the challenges faced by these countries, as well as the possibilities of improving access, this paper argues that while the waiver offers the best available solution to overcome the current supply shortages of a range of COVID-19 health products, in the longer term a break from this past—the decolonization of IP regimes—is necessary.

New Book – Intellectual Property Law and Access to Medicines: TRIPS Agreement, Health and Pharmaceuticals

[Srividhya Ragavan] Amaka Vanni and I are pleased to share our new book, Intellectual Property Law and Access to Medicines: TRIPS Agreement, Health, and Pharmaceuticals. The book maps 25 years of TRIPS from the perspective of access to medication discourse by looking at  three generations of access to medication debate.

The WTO TRIPS Waiver Should Help Build Vaccine Manufacturing Capacity in Africa

[Faizel Ismail] The current global health crisis created by the COVID-19 pandemic has re-focused our attention on the inadequacy of the TRIPS agreement and the patent system to address global public health crises. This time, developing countries must ensure that the TRIPS waiver succeeds in creating the impetus for the building of manufacturing capacity in the poorest countries, especially in Africa, for vaccines, pharmaceuticals and other health technologies. This is the only effective way in which African countries can reduce their dependence on imports of essential medicines and build their health security, contributing to the achievement of the sustainable development goals, for the poorest countries.

Call for Proposals: Global Congress on Intellectual Property and the Public Interest #IPWeek2021

From July 26 to September 10, the call for proposals will be open for the collaborative agenda of #IPWeek2021, Intellectual Property Week, the Public Interest, and COVID-19: learnings, discoveries, and challenges. This new version of Intellectual Property, Public Interest and COVID-19 Week will address the lessons and discoveries that the COVID-19 pandemic left to society, and future challenges in the post-pandemic period, in the relationship framework between intellectual property and the public interest.